A phase III randomised trial of LV 5 FU 2 1 irinotecan versus LV 5 FU 2 alone in adjuvant high-risk colon cancer ( FNCLCC Accord 02 / FFCD 9802 )

A phase III randomised trial of LV5FU2 1 irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802) M. Ychou*, J.-L. Raoul, J.-Y. Douillard, S. Gourgou-Bourgade, R. Bugat, L. Mineur, F. Viret, Y. Becouarn, O. Bouché, E. Gamelin, M. Ducreux, T. Conroy, J.-F. Seitz, L. Bedenne & A. Kramar CRLC Val d’Aurelle, Montpellier; CRLC Eugène Marquis, Rennes, France and European University in Brittany; CRLC René Gauducheau, St Herblain; CRLC Claudius Régaud, Toulouse; Clinique Sainte Catherine, Avignon; CRLC Antoine Lacassagne, Nice; Institut Bergonié, Bordeaux; CH R. Debré, Reims; CRLC Paul Papin, Angers; Institut Gustave Roussy, Villejuif; CRLC Alexis Vautrin, Vandoeuvre-les-Nancy; CH La Timone, Marseille; CHU du Bocage, Dijon, France